Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512358 | 1.00 | CNR2 (0.54) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL4566579 | 1.00 | CNR2 (0.54) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3513720 | 0.92 | CNR2 (0.57) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3516806 | 0.91 | CNR2 (0.56) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3514102 | 0.91 | CNR2 (0.56) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3512393 | 0.88 | CNR2 (0.58) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3513909 | 0.88 | CNR2 (0.58) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3512731 | 0.85 | EGLN1 (0.65) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3513022 | 0.81 | CNR2 (0.66) | CNR2CNR1PTGDR2EGLN1EGLN2 | |
| SCHEMBL3515172 | 0.77 | EGLN2 (0.46) | CNR2CNR1EGLN1EGLN2EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | claimed |
| EP-2136810-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008130527-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| EP-2136810-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008130527-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130527-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | HIF1AN, HIF1A, EGLN2 | CNR2 2485/4885CNR1 1567/4885PTGDR2 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.